Neuromuscular Disorders
Chronic progressive external ophthalmoplegia
Oct. 29, 2024
MedLink®, LLC
3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122
Toll Free (U.S. + Canada): 800-452-2400
US Number: +1-619-640-4660
Support: service@medlink.com
Editor: editor@medlink.com
ISSN: 2831-9125
Toll Free (U.S. + Canada): 800-452-2400
US Number: +1-619-640-4660
Support: service@medlink.com
Editor: editor@medlink.com
ISSN: 2831-9125
Associate Professor of Neurology and Human and Molecular Genetics
Vice Chair of Research in Neurology
Virginia Commonwealth University
Editorial Board Member since 2023: Neuromuscular Disorders
Clinical and Research Interests: Dr. Johnson's research is focused on inherited neuromuscular disorders. He received his undergraduate degree in molecular and cellular biology and psychology at the University of Arizona. He then obtained his medical degree at the University of Arizona. He completed his neurology residency and combined fellowship in neuromuscular medicine and experimental therapeutics at the University of Rochester.
He leads the GRASP-LGMD consortium, which focuses on developing clinical outcomes and biomarkers in the limb-girdle muscular dystrophies, and co-leads the Myotonic Dystrophy Clinical Research Network, which focuses on developing clinical outcomes and biomarkers in the myotonic dystrophies. Both networks include sites across the United States, Europe, Canada, and New Zealand with multiple natural history protocols. His laboratory is focused on identifying the pathogenesis and progression of myotonic dystrophy, and biomarkers in limb girdle muscular dystrophy. Johnson conducts therapeutic trials in many other inherited nerve and muscle disorders, including limb girdle muscular dystrophy, myotonic dystrophy, and facioscapulohumeral muscular dystrophy.
Dr. Johnson of Virginia Commonwealth University received consulting fees and/or research grants from AMO Pharma, Avidity, Dyne, Novartis, Pepgen, Sanofi Genzyme, Sarepta Therapeutics, Takeda, and Vertex, consulting fees and stock options from Juvena, and honorariums from Biogen Idec and Fulcrum Therapeutics as a drug safety monitoring board member.